
Tenax Therapeutics TENX
$ 1.83
0.54%
Tenax Therapeutics Deferred Revenue | TENX
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 125 K | 185 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 K | 125 K | 155 K |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbCellera Biologics
ABCL
|
13.5 M | $ 11.41 | 2.15 % | $ 3.41 B | ||
|
Aclaris Therapeutics
ACRS
|
3.94 M | $ 5.53 | 6.02 % | $ 678 M | ||
|
ADC Therapeutics SA
ADCT
|
834 K | $ 1.09 | 3.74 % | $ 139 M | ||
|
Amryt Pharma plc
AMYT
|
23 M | - | - | $ 621 M | ||
|
Chimerix
CMRX
|
1.54 M | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
2.75 M | - | - | $ 401 M | ||
|
ADMA Biologics
ADMA
|
143 K | $ 8.61 | 0.16 % | $ 2.05 B | ||
|
Fusion Pharmaceuticals
FUSN
|
333 K | - | - | $ 1.41 B | ||
|
Genocea Biosciences
GNCA
|
1.7 M | - | -15.0 % | $ 3.04 M | ||
|
Gritstone Oncology
GRTS
|
2.35 M | - | 0.42 % | $ 213 M | ||
|
G1 Therapeutics
GTHX
|
620 K | - | - | $ 370 M | ||
|
Harpoon Therapeutics
HARP
|
30.9 M | - | - | $ 763 M | ||
|
Humanigen
HGEN
|
883 K | - | -81.12 % | $ 4.28 M | ||
|
HOOKIPA Pharma
HOOK
|
4.76 M | - | -6.92 % | $ 79.4 M | ||
|
Intercept Pharmaceuticals
ICPT
|
1.62 M | - | - | $ 643 M | ||
|
IMV
IMV
|
139 K | - | - | $ 13.1 M | ||
|
Intra-Cellular Therapies
ITCI
|
1.67 M | - | - | $ 13.6 B | ||
|
Chinook Therapeutics
KDNY
|
95 K | - | - | $ 2.6 B | ||
|
Kaleido Biosciences
KLDO
|
828 K | - | -3.69 % | $ 12.4 M | ||
|
Kronos Bio
KRON
|
1.86 M | - | 1.49 % | $ 50.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
2.85 M | - | - | $ 154 M | ||
|
LogicBio Therapeutics
LOGC
|
10.6 M | - | - | $ 229 M | ||
|
Lumos Pharma
LUMO
|
56 K | - | - | $ 35.3 M | ||
|
Merrimack Pharmaceuticals
MACK
|
36.2 M | - | - | $ 216 M | ||
|
Mirati Therapeutics
MRTX
|
824 K | - | - | $ 3.3 B | ||
|
9 Meters Biopharma
NMTR
|
125 K | - | -42.97 % | $ 1.05 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
2.51 M | - | -19.68 % | $ 18.4 M | ||
|
Oncternal Therapeutics
ONCT
|
1.63 M | - | -24.12 % | $ 1.56 M | ||
|
Opiant Pharmaceuticals
OPNT
|
16.6 K | - | - | $ 109 M | ||
|
Orchard Therapeutics plc
ORTX
|
959 K | - | 1.02 % | $ 90.8 M |